Lexicon Pharmaceuticals | LXRX - Passivo Circulante





Passivo Circulante Alterar Data
Abbott USD 18.38B 1.88B 2026-03
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Illumina USD 1.57B 19M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
J&J USD 57.72B 3.59B 2026-03
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
MannKind USD 134.56M 36.47M 2026-03
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Novartis USD 31.37B 4.1B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Thermo Fisher Scientific USD 14.62B 568M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12